Product Categories

GSK429286A

GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.

Catalog No.S1474
Price Stock Quantity  
USD 180 In stock
USD 680 In stock
Contact Us Bulk Inquiry Add to Wishlist

Free Overnight Delivery on all orders over $ 500.

Order now and get it on

Tel: +1-832-582-8158[email protected]
GSK429286A Chemical Structure

GSK429286A Chemical Structure
Molecular Weight: 432.37

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

GSK429286A is available in the following compound libraries:

Chemical Library (96-well) Inhibitor Library (96-well) Stem Cell Small Molecule Compound Library (96-well)

Product Information

  • Compare ROCK Inhibitors
    Compare ROCK Inhibitors
  • Research Area

Product Description

Biological Activity Protocol Chemical Information Tech Support & FAQs

Biological Activity

Description GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.
Targets ROCK1 ROCK2
IC50 14 nM [1] 63 nM [2]
In vitro GSK429286A slightly inhibits RSK and p70S6K with IC50 of 0.78 μM and 1.94 μM, respectively. GSK429286A significantly inhibits rat aortic ring dilation with IC50 of 190 nM. [1] GSK429286A at 1 μM reduces ROCK2 activity over 20-fold, under conditions in which the only other kinase tested that is significantly inhibited is MSK1 whose activity is reduced ~5-fold. GSK429286A is a more selective ROCK2 inhibitor than the widely utilized ROCK inhibitor Y-27632 as assessed on kinase-specificity panel, and does not significantly inhibit LRRK2 even at doses as high as 30 μM (500-fold higher than IC50 of inhibition of ROCK2). Like GSK269962A but not sunitinib, GSK429286A treatment at 10 μM ablates basal or G14V-Rho mutant induced phosphorylation of MYPT at Thr850 in HEK-293 cells to a similar extent as H-1152 and Y-27632, consistent with ROCK mediating this phosphorylation, whereas GSK429286A does not inhibit ERM protein phosphorylation either in the presence or absence of G14V-Rho. [2]
In vivo GSK429286A has 61% oral bioavailability in male Sprague-Dawley rats. Oral administration of GSK429286A at single doses of 3-30 mg/kg dramatically reduces mean arterial pressure in the spontaneously hypertensive rats (SHRs) in a dose-dependent manner, with a maximum decrease of 50 mmHg after approximately 2 hours treatment at dose of 30 mg/kg. [1]
Clinical Trials
Features More selective than Y-27632.

Protocol(Only for Reference)

Kinase Assay: [1]

ROCK1 kinase assays GSK429286A is dissolved at 10 mM in 100% DMSO, with subsequent serial dilution in 100% DMSO. ROCK1 inhibitor activity is determined using human recombinant His-tag ROCK1 kinase domain (amino acid 2-543) expressed in Sf9 cells. Assays of ROCK1 activity are performed in opaque, white walled, 384 well plates, in a total assay volume of 20 μL. The assays contain: 1 nM hROCK1; 1 μM biotinylated peptide (biotin-Ahx-AKRRRLSSLRA-CONH2); 1 μM ATP; 1.85 kBq per well ATP(γ-33P); 25 mM Hepes pH 7.4; 15 mM MgCl2; 0.015% BSA; increasing concentrations of GSK429286A ranging from 50 μM to 0.8 nM. The reactions are incubated at 22°C for 120 minutes, and then terminated by the addition of a 50 μL solution containing 60 mM EDTA and streptavidin PVT SPA beads. The SPA beads are added to a concentration of 0.14 mg per well. The plates are allowed to incubate at 22°C for 10 minutes before centrifugation at 1500 rpm for 1 minute. P33 incorporation is quantified by scintillation counting in a Packard TopCount. IC50 value is calculated by bespoke curve fitting software.
ROCK2 kinase assays ROCK2 kinase assays are set up in a total volume of 40 μL with recombinant His6-ROCK2-(2-543) (80 ng, corresponding to 30 nM ROCK2 in the final kinase assay) in 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 0.1 mM [γ-32P]ATP (~500-1000 c.p.m./pmol), indicated concentration of peptide substrate, and increasing concentrations of GSK429286A dissolved in DMSO at 0.1% of the reaction volume. After incubation for 15 minutes at 30 °C, reactions are terminated by applying 35 μL of the reaction mixture on to P81 phosphocellulose paper and immersion in 50 mM phosphoric acid. After extensive washing, reaction products are quantified by Cerenkov counting. IC50 value is calculated using non-linear regression analysis using GraphPad Prism.

Animal Study: [1]

Animal Models Male spontaneously hypertensive rats (SHRs)
Formulation Formulated in 6% Hydroxypropyl-β-Cyclodextrin (pH4.0) and 5% DMSO solution
Dosages ~30 mg/kg
Administration Oral gavage
1

References

Chemical Information

Download GSK429286A SDF
Molecular Weight (MW) 432.37
Formula

C21H16F4N4O2
CAS No. 864082-47-3
Synonyms N/A
Solubility (25°C)
  • DMSO 87 mg/mL
  • Water <1 mg/mL
  • Ethanol 4 mg/mL
Storage 2 years -20°CPowder
2 weeks4°Cin DMSO
6 months-80°Cin DMSO
Chemical Name N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-(4-(trifluoromethyl)phenyl)-1,4,5,6-tetrahydropyridine-3-carboxamide
Molarity Calculator Dilution Calculator Molecular Weight Calculator

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions
Tel: +1-832-582-8158 Ext:3Monday–Friday 9:00 AM–5:00 PM (Central Time)

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related ROCK Inhibitors

  • Y-27632 2HCl

    Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM.

  • Thiazovivin

    Thiazovivin (Tzv) is a novel ROCK inhibitor with IC50 of ~0.5 μM.

  • VX-680 (MK-0457, Tozasertib)

    VX-680 (MK-0457, Tozasertib) is a pan-Aurora inhibitor of Aurora A, Aurora B and Aurora C with Kiapp of 0.6 nM, 18 nM and 4.6 nM, respectively.

  • MLN8054

    MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM.

  • ZM-447439

    ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively.

  • Danusertib (PHA-739358)

    Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively.

  • BI 2536

    BI 2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM.

  • PD 0332991 (Palbociclib) HCl

    PD 0332991 is a highly selective inhibitor of CDK4/cyclin D1 and CDK6/cyclin D2 with IC50 of 11 nM and 16 nM, respectively.

  • MLN8237 (Alisertib)

    MLN8237 (Alisertib) is a selective Aurora A inhibitor with IC50 of 1.2 nM.

  • SNS-032 (BMS-387032)

    SNS-032 is a novel, potent and selective CDK inhibitor of CDK2, CDK7 and CDK9 with IC50 of 38 nM, 62 nM and 4 nM, respectively.

Cell Cycle and DNA Damage Related Products

> Download

Recently Viewed Items

Tags: buy GSK429286A | GSK429286A supplier | purchase GSK429286A | GSK429286A cost | GSK429286A manufacturer | order GSK429286A | GSK429286A distributor
Contact Us